Nicolai Eleonora, Tomassetti Flaminia, Pelagalli Martina, Sarubbi Serena, Minieri Marilena, Nisini Alberto, Nuccetelli Marzia, Ciotti Marco, Pieri Massimo, Bernardini Sergio
Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy.
Department of Laboratory Medicine, Tor Vergata University Hospital, Viale Oxford 81, 00133 Rome, Italy.
Biomedicines. 2023 Sep 28;11(10):2661. doi: 10.3390/biomedicines11102661.
The use of vaccines has allowed the containment of coronavirus disease 2019 (COVID-19) at a global level. The present work aims to add data on vaccination by evaluating the level of neutralizing antibodies in individuals who have received a three-vaccination series. For this purpose, we ran a surveillance program directed at measuring the level of IgG Abs against the Receptor Binding Domain (RBD) and surrogate virus neutralizing Ab (sVNT) anti-SARS-CoV-2 in the serum of individuals undergoing vaccination. This study was performed on employees from the University of Rome Tor Vergata and healthcare workers from the University Hospital who received the Vaxzevria vaccine (n = 56) and Comirnaty vaccine (n = 113), respectively. After the second dose, an increase in both RBD and sVNT Ab values was registered. In individuals who received the Comirnaty vaccine, the antibody titer was about one order of magnitude higher after 6 months from the first dose. All participants in this study received the Comirnaty vaccine as the third dose, which boosted the antibody response. Five months after the third dose, nearly one year from the first injection, the antibody level was >1000 BAU/mL (binding antibody units/mL). According to the values reported in the literature conferring protection against SARS-CoV-2 infection, our data indicate that individuals undergoing three vaccine doses present a low risk of infection.
疫苗的使用使得2019冠状病毒病（COVID-19）在全球范围内得到了控制。本研究旨在通过评估接受三剂疫苗接种的个体的中和抗体水平来补充疫苗接种相关数据。为此，我们开展了一项监测计划，旨在测量接种疫苗个体血清中针对受体结合域（RBD）的IgG抗体水平以及替代病毒中和抗体（sVNT）抗SARS-CoV-2水平。本研究分别对罗马第二大学的员工和大学医院的医护人员进行，他们分别接种了Vaxzevria疫苗（n = 56）和Comirnaty疫苗（n = 113）。在接种第二剂疫苗后，RBD和sVNT抗体值均有所升高。在接种Comirnaty疫苗的个体中，从第一剂接种后6个月起，抗体滴度高出约一个数量级。本研究的所有参与者均接种Comirnaty疫苗作为第三剂，这增强了抗体反应。在接种第三剂疫苗五个月后，即首次注射近一年后，抗体水平>1000 BAU/mL（结合抗体单位/毫升）。根据文献中报道的可提供针对SARS-CoV-2感染保护作用的值，我们的数据表明，接受三剂疫苗接种的个体感染风险较低。
